Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
  1. SFA_Sales_Revenues_September_2025_EN_espi.pdfSales revenues for September 2025

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 204 / 2025
Date of issue: 2025-10-21
Short name of the issuer
SOPHARMA AD
Subject
Sales revenues for September 2025
Official market - legal basis
Art. 56. 1. 2 of Act on Public Offering
Unofficial market - legal basis
Contents of the report:
“Sopharma” AD notifies, that for September 2025 the Company recorded increase in sales of 24% compared to the same month of the previous year, incl. 10% increase in domestic sales and 38% increase in export sales.
For the period from the beginning of 2025, the Company realized a 7% increase in sales, including 2% decrease in domestic sales and a 13% increase in export sales.
Annexes
File Description
SFA_Sales_Revenues_September_2025_EN_espi.pdf
SFA_Sales_Revenues_September_2025_EN_espi.pdf		 Sales revenues for September 2025

SOPHARMA AD
(fullname of the issuer)
SOPHARMA AD Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
1220 Sofia
(post code) (city)
IlienskoShosse 16
(street) (number)
+359 2 813 42 00 +359 2 936 02 86
(phone number) (fax)
(e-mail) (web site)
nd
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2025-10-21 Ognian Ivanov Donev Executive Director
20251021_134118_0586794181_SFA_Sales_Revenues_September_2025_EN_espi.pdf

Pobierz